Trevena Inc
TRVN
$0.39
Closing
▲4.81%
1D
▼-45.01%
YTD
Market cap
$7.11M
52 week high
$3.28
52 week low
$0.31
Volume
13,056
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$7.11M
Analysts' Rating
BUY
Price Target (Mean)
6.5
Total Analysts
1
P/E
Operating Margin
-4903.89%
Beta
1.12
Revenue Growth (Annual)
-173.72%
52 week high
$3.28
52 week low
$0.31
Div. Yield
%
EPS Annual Growth
-17.39
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Trevena, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company’s product, OLINVYK (oliceridine) injection, is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. It is also engaged in three differentiated investigational drug candidates: TRV045, TRV250, and TRV734. TRV045 is a novel sphingosine-1-phosphate (S1P), receptor modulator that may offer a new, non-opioid approach to managing chronic pain, as well as treating epilepsy and seizure disorders. TRV250 is a G-protein biased delta-opioid receptor (DOR), agonist as a compound with a mechanism for the treatment of acute migraine. TRV734 is a new chemical entity (NCE) targeting the same mechanism of action at the mu-opioid receptor (MOR). TRV734 is used for the treatment of opioid use disorder.
